Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs ProShares Ultra Semiconductors (USD) Price & Performance

Mesoblast LimitedTrade
ProShares Ultra SemiconductorsTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs ProShares Ultra Semiconductors — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while ProShares Ultra Semiconductors trades at $90. The key difference: ProShares Ultra Semiconductors is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

MESOUSD
Market Cap
$2.16B
Sector
TechnologyLeveraged / Inverse
52-Week High
$20.96$113.53
52-Week Low
$12.88$40.97
Enterprise Value
$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

ProShares Ultra Semiconductors

USD stock trades at $93.67, up 3.46% in the past 24 hours, with technical indicators signaling a bullish trend. The stock shows strong momentum above key support levels, though the RSI_6 at 99.69 suggests overbought conditions. A dividend of $0.14 is scheduled for June 30, 2026. Recent news highlights corporate developments in financial services and technology sectors.

The outlook remains positive given bullish technical signals and corporate actions, but high RSI indicates potential near-term pullback risks. Investors should weigh the dividend yield against valuation concerns amid limited fundamental data availability. Market sentiment is mixed, with institutional interest balanced by overbought technicals.

Returns comparison

Trailing returns across standard periods

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About ProShares Ultra Semiconductors

USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.

Read more on USD